Photocure Enters into Final Agreement to Regain Worldwide Rights of Hexvix
Oslo, Norway, 11 June 2020: Reference is made to the OSE notification 27 April 2020 from Photocure ASA (Photocure, PHO: OSE) regarding the return of Hexvix[®] sales, marketing and distribution rights in Europe and other markets currently controlled by Ipsen Pharma SAS (Ipsen). Photocure and Ipsen have today entered into a final agreement.“We have entered into a final agreement with Ipsen that will have a transformative impact on Photocure, in line with our strategy of building a strong and profitable global business within the diagnosis and treatment of bladder cancer. We have built a